New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment

Author： Dastiridou Anna Kalogeropoulos Christos Brazitikos Periklis Symeonidis Chrysanthos Androudi Sofia

ISSN： 1751-2433

Source： Expert Review of Clinical Pharmacology, Vol.5, Iss.5, 2012-09, pp. : 543-555

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease

Current Drug Targets, Vol. 11, Iss. 2, 2010-02 ,pp. : 198-218

Bentham Science Publishers

Access to resources Recommend Favorite

“How to Manage Loss of Response to Anti-TNF in Crohn's Disease?”

Current Drug Targets, Vol. 11, Iss. 2, 2010-02 ,pp. : 152-155

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-TNF agents for the treatment of spondyloarthropathies

By Sieper Joachim Braun Jürgen

Expert Opinion on Emerging Drugs, Vol. 7, Iss. 2, 2002-10 ,pp. : 235-246

Informa Healthcare

Access to resources Recommend Favorite

Anti-TNF Treatment in Rheumatoid Arthritis

Current Pharmaceutical Design, Vol. 17, Iss. 29, 2011-10 ,pp. : 3141-3151

Bentham Science Publishers

Access to resources Recommend Favorite

Utility of Measuring Serum Concentrations of Anti-TNF Agents and Anti-Drug Antibodies in Inflammatory Bowel Disease

Current Drug Metabolism, Vol. 12, Iss. 6, 2011-07 ,pp. : 594-598

Bentham Science Publishers

Access to resources Recommend Favorite